Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Lymphoma, T-Cell, Cutaneous 7Lymphoma 7Sezary Syndrome 5Immunoblastic Lymphadenopathy 5Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Melanoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Subcutaneous panniculitis-like T-cell lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Skin Neoplasms 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Chronic 2

Interventions

HhAntag691 25Imiquimod 12Biopsy 12sonidegib 11Aminolevulinic Acid 9cemiplimab 8Photochemotherapy 8Nivolumab 8methyl 5-aminolevulinate 7Mohs Surgery 71-phenyl-3,3-dimethyltriazene 7Tomography, Optical Coherence 6Surgical Procedures, Operative 6Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Microscopy, Confocal 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Standard of Care 3Niacinamide 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × Prednisone × Dermatologic × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡